Exchange Traded Concepts LLC Increases Stake in STERIS plc (NYSE:STE)

Exchange Traded Concepts LLC increased its holdings in STERIS plc (NYSE:STEFree Report) by 27.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 789 shares of the medical equipment provider’s stock after purchasing an additional 170 shares during the quarter. Exchange Traded Concepts LLC’s holdings in STERIS were worth $162,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Ashton Thomas Securities LLC bought a new position in shares of STERIS during the third quarter valued at about $25,000. Central Pacific Bank Trust Division purchased a new stake in STERIS during the 3rd quarter valued at about $28,000. Quarry LP bought a new position in STERIS during the 3rd quarter worth approximately $67,000. Asset Dedication LLC increased its stake in STERIS by 54.8% in the 3rd quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock worth $71,000 after purchasing an additional 103 shares during the period. Finally, Axxcess Wealth Management LLC bought a new stake in STERIS in the third quarter valued at approximately $203,000. 94.69% of the stock is owned by institutional investors.

STERIS Price Performance

STE stock opened at $220.84 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 1.55. STERIS plc has a 1 year low of $197.82 and a 1 year high of $248.24. The firm has a 50-day moving average of $212.15 and a 200 day moving average of $224.73. The company has a market cap of $21.80 billion, a P/E ratio of 50.42 and a beta of 0.84.

STERIS (NYSE:STEGet Free Report) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the prior year, the company earned $2.03 EPS. The business’s revenue was up 7.3% compared to the same quarter last year. On average, sell-side analysts forecast that STERIS plc will post 9.11 EPS for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, February 20th. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Insider Transactions at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares in the company, valued at $2,471,363.04. This represents a 12.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Monday, November 18th. Stephens restated an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research report on Thursday, November 7th. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and an average price target of $262.50.

Check Out Our Latest Stock Report on STERIS

About STERIS

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Stories

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.